TherapeuticsMD, Inc. (NASDAQ:TXMD) saw a large growth in short interest during the month of December. As of December 29th, there was short interest totalling 55,882,896 shares, a growth of 4.4% from the December 15th total of 53,505,064 shares. Based on an average daily volume of 2,720,761 shares, the days-to-cover ratio is currently 20.5 days. Approximately 32.1% of the company’s stock are short sold.

Shares of TherapeuticsMD (TXMD) opened at $6.24 on Friday. The stock has a market cap of $1,350.00, a PE ratio of -16.00 and a beta of 1.06. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. The firm had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The business’s quarterly revenue was down 19.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.13) EPS. analysts predict that TherapeuticsMD will post -0.37 earnings per share for the current year.

In other news, Director Tommy G. Thompson acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 8th. The shares were bought at an average cost of $6.21 per share, with a total value of $31,050.00. Following the transaction, the director now owns 3,555 shares of the company’s stock, valued at approximately $22,076.55. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 23.92% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Candriam Luxembourg S.C.A. boosted its holdings in shares of TherapeuticsMD by 10.4% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 530,000 shares of the company’s stock valued at $2,804,000 after acquiring an additional 50,000 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of TherapeuticsMD by 10.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after buying an additional 67,855 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of TherapeuticsMD by 26.6% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 142,930 shares of the company’s stock worth $756,000 after buying an additional 30,030 shares during the last quarter. Swiss National Bank boosted its holdings in shares of TherapeuticsMD by 12.3% in the third quarter. Swiss National Bank now owns 289,800 shares of the company’s stock worth $1,533,000 after buying an additional 31,800 shares during the last quarter. Finally, Stifel Financial Corp boosted its holdings in shares of TherapeuticsMD by 377.9% in the second quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock worth $10,820,000 after buying an additional 1,622,668 shares during the last quarter. 73.69% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts recently commented on the stock. Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a research report on Friday, December 29th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $28.00 price target on shares of TherapeuticsMD in a report on Sunday, January 7th. BidaskClub raised shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Oppenheimer set a $10.00 price target on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday, December 20th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $15.00 price target on shares of TherapeuticsMD in a report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. TherapeuticsMD has an average rating of “Buy” and an average target price of $14.50.

WARNING: “TherapeuticsMD, Inc. (TXMD) Sees Significant Growth in Short Interest” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/therapeuticsmd-inc-txmd-sees-significant-growth-in-short-interest/1803746.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with Analyst Ratings Network's FREE daily email newsletter.